Platelet recovery rate during plasma exchange predicts early and late responses in patients with thrombotic thrombocytopenic purpura (CME)

Transfusion

Volumn 53, Issue 5, 2013, Pages 1096-1107

  Liu, Chang ^a   Kallogjeri, Dorina ^a   Dynis, Marian ^a   Grossman, Brenda J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PLATELET RECOVERY RATE; POST TREATMENT SURVIVAL; PROGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; THROMBOCYTE FUNCTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADULT; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA EXCHANGE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877722288     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03857.x     Document Type: Article

References (26)

1. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
2. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
3. Feys HB, Roodt J, Vandeputte N, Lamprecht S, van Rensburg WJ, Anderson PJ, Budde U, Louw VJ, Badenhorst PN, Deckmyn H, Vanhoorelbeke K,. Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood 2010; 116: 2005-10.
4. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA,. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-7.
5. Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF,. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007; 17: 17-35.
6. Henon P,. [Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study]. Presse Med 1991; 20: 1761-7.
7. Amorosi EL, Ultmann JE,. Thrombocytopic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45: 139-59.
8. Kim JW, Kim I, Oh KH, Yoon SS, Oh MD, Song YW, Heo DS, Bang YJ, Han KS, Han JS, Park S, Kim BK,. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. Hematology 2011; 16: 73-9.
9. Altuntas F, Aydogdu I, Kabukcu S, Kocyigit I, Cikim K, Sari I, Erkut MA, Eser B, Ozturk A, Kaya E, Cetin M, Keskin A, Unal A,. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci 2007; 36: 57-67.
10. Sadler JE,. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11-8.
11. Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN,. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11.
12. Verbeke L, Delforge M, Dierickx D,. Current insight into thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2010; 21: 3-10.
13. Cataland SR, Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM,. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 2009; 83: 559-64.
14. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE,. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9.
15. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T,. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100.
16. Miyata T, Kokame K, Banno F,. Measurement of ADAMTS13 activity and inhibitors. Curr Opin Hematol 2005; 12: 384-9.
17. Bandarenko N, Brecher ME,. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998; 13: 133-41.
18. George JN,. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (Experience of The Oklahoma TTP-HUS Registry, 1989-2007). Kidney Int Suppl 2009;(112): S8-S10.
19. George JN,. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl 2009;(112): S52-4.
20. George JN,. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116: 4060-9.
21. George JN, Vesely SK, Terrell DR,. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004; 41: 60-7.
22. Clark WF,. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial 2012; 25: 214-9.
23. Fakhouri F, Fremeaux-Bacchi V,. Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007; 3: 679-87.
24. Davis AK, Makar RS, Stowell CP, Kuter DJ, Dzik WH,. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009; 49: 206-13.
25. Tandon NN, Rock G, Jamieson GA,. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88: 816-25.
26. Schultz DR, Arnold PI, Jy W, Valant PA, Gruber J, Ahn YS, Mao FW, Mao WW, Horstman LL,. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 1998; 103: 849-57.